Rationale, Design, and Baseline Data of the Insulin Glargine (Lantus) Versus Insulin Detemir (Levemir) Treat-To-Target (L2T3) Study: A Multinational, Randomized Noninferiority Trial of Basal Insulin Initiation in Type 2 Diabetes
- 1 November 2009
- journal article
- research article
- Published by Mary Ann Liebert Inc in Diabetes Technology & Therapeutics
- Vol. 11 (11), 739-743
- https://doi.org/10.1089/dia.2009.0044
Abstract
Objective: To discuss the design and baseline data of the Lantus® (sanofi-aventis, Paris, France) versus Levemir® (Novo Nordisk A/S, Bagsværd, Denmark) Treat-To-Target (L2T3) study, a multinational, randomized comparison between the basal insulin analogs insulin glargine and insulin detemir. Methods: Insulin-naive subjects with type 2 diabetes suboptimally controlled on oral glucose-lowering drugs (OGLDs) (including at least metformin) were randomized to 24-week treatment with either insulin glargine once-daily or insulin detemir twice-daily, titrated to obtain fasting plasma glucose Results: Recruitment was completed in November 2007. The majority of the randomized population (n = 973) was white (77.8%) and used one other OGLD beside metformin (70.7%). Concerning patient-reported outcomes, ∼20% of subjects reported no physical symptoms of fatigue or hyperglycemia before insulin initiation, and ∼10% were maximally satisfied with their previous treatment. One-third of patients (29.9%) reported suboptimal well-being, and 9.3% had a score indicating depression. Better emotional well-being was significantly associated with lower diabetes symptom distress and higher treatment satisfaction (respectively, r = −0.56 and 0.41; P < 0.001). Conclusions: The L2T3 study will extend the evidence on both the efficacy and the effects on quality of life and treatment satisfaction of the long-acting insulin analogs glargine and detemir. Additionally, it will increase our understanding of the factors important to the (self-)management of type 2 diabetes patients starting insulin.Keywords
This publication has 23 references indexed in Scilit:
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia, 2008
- Transition to insulin in Type 2 diabetes: family physicians' misconception of patients' fears contributes to existing barriersJournal of Diabetes and its Complications, 2007
- Nice insulins, pity about the evidenceDiabetologia, 2007
- Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly Controlled Type 2 DiabetesClinical Therapeutics, 2006
- A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 DiabetesDiabetes Care, 2006
- The Burden of Treatment Failure in Type 2 DiabetesDiabetes Care, 2004
- The Treat-to-Target TrialDiabetes Care, 2003
- Initial Management of Glycemia in Type 2 Diabetes MellitusNew England Journal of Medicine, 2002
- Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year studyDiabetes Research and Clinical Practice, 1995